09.10.13
DFINE Inc., a developer of treatments for spinal diseases has named Greg Barrett as president and CEO. Barrett assumes those roles from Kevin Mosher who, after four years, is returning to the dental field as CEO of ClearChoice in Denver, Colo.
Barrett brings more than 35 years of medical technology leadership experience to the privately held company. Most recently, he was chairman, president and CEO of BÂRRX Medical, where he guided the company’s $325 million sale to Covidien in 2012. Before joining BÂRRX in 2004, he served as president and CEO of ACMI Corporation; group executive vice president at Boston Scientific Corp.; and held positions as vice president, global sales and marketing at Orthofix Corp. and Baxter Healthcare. He also spent 13 years at C.R. Bard Corp., where he was vice president of Marketing in the Cardiosurgery Division. Greg sits on the board of Monteris Medical, BaroSense Inc. and Cutera Inc. He holds a B.A. in Marketing from the University of Texas, Austin.
“After looking at a number of opportunities following Covidien’s acquisition of BÂRRX, DFINE stood out because of its innovative technology platform including the STAR tumor ablation system for the treatment of painful spinal tumors and the StabiliT system for vertebral compression fracture repair," Barrett said in a statement. "Both products represent very innovative solutions for the hundreds of thousands of patients suffering from these debilitating diseases of the spine. Patients, physicians and the healthcare system will greatly benefit as we expand availability of these therapies.”
San Jose, Calif.-based DFINE is focused on technology for the treatment of spinal paing.
The company's devices are built using a radiofrequency (RF) platform. Cleared for commercial use by the U.S. Food and Drug Administration (FDA), the first application was the StabiliT vertebral augmentation system and StabiliT ER2 bone cement, which use RF energy to treat pathological fractures of the vertebrae. The company subsequently received FDA 510(k) clearance for its second application, the STAR ablation system, for palliative treatment in spinal procedures to ablate metastatic malignant lesions in a vertebral body. The STAR system will be commercially released later this year.
Barrett brings more than 35 years of medical technology leadership experience to the privately held company. Most recently, he was chairman, president and CEO of BÂRRX Medical, where he guided the company’s $325 million sale to Covidien in 2012. Before joining BÂRRX in 2004, he served as president and CEO of ACMI Corporation; group executive vice president at Boston Scientific Corp.; and held positions as vice president, global sales and marketing at Orthofix Corp. and Baxter Healthcare. He also spent 13 years at C.R. Bard Corp., where he was vice president of Marketing in the Cardiosurgery Division. Greg sits on the board of Monteris Medical, BaroSense Inc. and Cutera Inc. He holds a B.A. in Marketing from the University of Texas, Austin.
“After looking at a number of opportunities following Covidien’s acquisition of BÂRRX, DFINE stood out because of its innovative technology platform including the STAR tumor ablation system for the treatment of painful spinal tumors and the StabiliT system for vertebral compression fracture repair," Barrett said in a statement. "Both products represent very innovative solutions for the hundreds of thousands of patients suffering from these debilitating diseases of the spine. Patients, physicians and the healthcare system will greatly benefit as we expand availability of these therapies.”
San Jose, Calif.-based DFINE is focused on technology for the treatment of spinal paing.
The company's devices are built using a radiofrequency (RF) platform. Cleared for commercial use by the U.S. Food and Drug Administration (FDA), the first application was the StabiliT vertebral augmentation system and StabiliT ER2 bone cement, which use RF energy to treat pathological fractures of the vertebrae. The company subsequently received FDA 510(k) clearance for its second application, the STAR ablation system, for palliative treatment in spinal procedures to ablate metastatic malignant lesions in a vertebral body. The STAR system will be commercially released later this year.